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Abstract
Background: Recent in vitro studies provide evi-
dence that the cell cycle molecules pRb, p53 and
MDM2 form a tightly regulated protein network. In
this study, we examined the relationship of this pro-
tein network in a series of non-small cell lung carci-
nomas (NSCLCs), with the kinetic parameters, in-
cluding proliferative activity or proliferation index
(PI) and apoptotic index (AI), and ploidy status of
the tumors. 
Material and Methods: A total of 87 NSCLCs were
examined using immunohistochemical and molecu-
lar methods in order to estimate the status of the
pRb-p53-MDM2 network. The kinetic parameters
and the ploidy status of the tumors were assessed by
in situ assays. The possible associations between al-
terations of the network, kinetic parameters and
ploidy status of the carcinomas were assessed with a
series of statistical methods. 
Results: Aberrant expression of pRb (Ab) and over-
expression of p53 (P) and MDM2 (P) proteins were
observed in 39%, 57%, and 68% of the carcinomas,
respectively. The comprehensive analysis revealed
that concurrent alterations in all three cell cycle reg-
ulatory molecules were the most frequent pattern,
pRb(Ab)/p53(P)/MDM2(P); this “full abnormal”
phenotype represented approximately 27% of the
cases. This immunoprofile obtained the highest
PI/AI value; whereas, the “normal” phenotype was
the lowest one (p  0.004). Furthermore, the pattern
pRb(Ab)/p53(P)/MDM2(P) acquired the highest PI
(p  0.001) and lowest AI (p  0.001) scores. Inter-
estingly, the groups of carcinomas with impaired
expression of one or two molecules attained PI/AI
ratio values clustered in a narrow range placed in
the middle of the scores exhibited by the “normal”
and “full abnormal” phenotypes. These tumors had
significantly lower AI, but similar PI values, com-
pared with those noticed in the normal pattern. In
addition, it was observed that the pRb(Ab)/p53(P)/
MDM2(P) phenotype was also significantly associ-
ated with aneuploidy (p  0.002) and a tendency
was observed when the expression of two compo-
nents was altered (p  0.055).   
Conclusions: Our findings suggest that simultane-
ous deregulation of all members of the  pRb-p53-
MDM2 network confers an additive effect on tumor
growth. The apoptotic pathway seems to be more
susceptible to its defects than the cell proliferation
machinery. The findings of the ploidy analysis,
which are in parallel with those regarding the pro-
liferative activity and the apoptotic rate study, fur-
ther support the concept that these molecules consti-
tute a tightly regulated network participating in cell
cycle control and chromosomal stability.
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Introduction
Physiological cells possess protective mecha-
nisms that sense stress and oncogenic signals.
When sensing stress, the cells trigger counter-
measures in order to limit the deleterious effect
(1); whereas, with oncogenic signals they will
react by controlling proliferative activity (2).
The dominant factors in this response are the
p53 and pRb tumor-suppressor proteins. Alter-
ations in these molecules represent two of the
most common phenomena in human malig-
nancies (3,4).
The pRb protein is a 105kDa nuclear phos-
phoprotein, which belongs to the “pocket” pro-
tein family that also includes p107 and p130.
The main function of pRb is to control cell cy-
cle progression through the G1 phase. This oc-
curs when pRb interacts in its dephosphory-
lated form with a multitude of cellular factors
that regulate gene expression at various levels
(5,6). Gradual phosphorylation of pRb, cat-
alyzed by cyclin-dependent kinases (CDKs),
inactivates its growth suppressive activity;
whereas, members of the CDK inhibitor fami-
lies control this process, thus, forming a tightly
guided pathway (5,7). Another important but
paradoxical function, for an oncosuppressor
protein like pRb, is that lack of its activity not
only leads to apoptosis, but restoration of func-
tional pRb directly inhibits its activity (8). The
wild-type (wt) p53 protein, on the other hand,
is a vital G1/S and G2/M “checkpoint” factor
that monitors DNA-damage, as well as other
stress signals, inducing either cell cycle arrest
or apoptosis (9). The activities of p53 are
mainly governed by its downstream effector
MDM2. The MDM2 gene is directly activated by
p53 and expresses its product, which interacts
with p53 forming a regulatory feedback loop
(9). The assembled MDM2-p53 complex then
targets p53 for ubiquitin-mediated proteolysis,
thus, reducing its levels (10,11). At first sight,
the regulation of the p53 and pRb path-
ways appears to be distinctly different, with
p21WAF1/Cip1 being the mere indirect link be-
tween them. The WAF1/Cip1 gene is a down-
stream target of p53, encoding the p21WAF1/Cip1
CDK2 inhibitor, hence controlling the phos-
phorylation status of pRb (9). However, a re-
cent report demonstrated that the C pocket do-
main of pRb (residues 792–928) binds to the
C-terminal domain (residues 273–321) of the
MDM2 protein, leaving its p53 binding do-
main free, which lies within the N-terminal re-
gion (Fig. 1) (12). Furthermore, another study
showed that binding of pRb to MDM2 inhibits
the anti-apoptotic function of MDM2 by pre-
venting the MDM2-dependent degradation of
p53 (13). This close interaction between the
pRb and p53 pathways, via MDM2, reveals
clearly that these major cell cycle regulatory
routes actually represent parts of the same net-
work. The intriguing point in this relationship
is that two classical oncosuppressors are asso-
ciated with the same protein, which has been
shown to act as an oncoprotein (14,15). The
MDM2 gene seems to exert its tumorigenic 
effects by two mechanisms: overexpression
(14,15) and production of alternative splice
variants, which add novel oncogenic properties
to the cell (16,17). Deregulated expression of
MDM2 has been found in various tumors, in-
cluding sarcomas (18), glioblastomas (19),
breast carcinomas (20), urothelial cancers (21),
lung carcinomas (22–25) and hematological
malignancies (26). Nevertheless, a recent study
showed that the MDM2 protein has the abil-
ity to inhibit cell cycle progression in a p53-
independent manner, creating a complicated
picture of its role in cell cycle regulation (27).
This finding, together with those mentioned
above, point out the need to examine the status
of the pRb-MDM2-p53 pathway in human ma-
lignancies and the consequences of its defects
on tumor kinetics. 
Another factor that should be considered in
association with these proteins is chromosomal
instability (CIN). CIN occurs in most human
malignancies and reflects gains or losses of
segments or whole chromosomes, and leads to
an abnormal chromosomal quantity (aneu-
ploidy) (28). The mechanism that underlies
this common cancerous phenomenon is just
beginning to be investigated and involves al-
terations of genes implicated in replication,
chromosome condensation and segregation, as
well as inactivation of “checkpoint” genes that
monitor DNA-damage and proper assemblage
of the mitotic spindle apparatus (29). It is rea-
sonable to assume that altered expression of a
checkpoint protein, like p53, due to mutations
or deregulated control, will participate in such
a procedure. Although several reports support
this assumption (30–32), others show that loss
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of wt p53 does not abolish the mitotic spindle
checkpoint (33,34). 
Recently, we analyzed the p16/pRb/p53/
MDM2 network in a series of NSCLCs and
found that concurrent abnormalities of pRb,
p53 and MDM2 occurred in approximately
30% of the tumors examined, representing the
most frequent expression pattern (24). The ap-
parent involvement of this trimeric network in
tumor progression led us to investigate, in an
extended NSCLC database (24), its relationship
first with the kinetic parameters of proliferation
and apoptosis, which actually determine the
growth rate of a tumor (35), and second with
the ploidy status of the carcinomas.
Materials and Methods
Tissue Samples
A total of 87 NSCLCs and adjacent normal lung
tissues were obtained from surgically treated
patients (mean age: 63.4 years). For 70 tumor
samples, snap-frozen samples in liquid nitro-
gen, stored at 70oC, and formalin-fixed and
paraffin-embedded (FFPE) material was avail-
able. For the remaining 17 samples, only FFPE
material was accessible. The patients had not
undergone any chemotherapy or radiotherapy
prior to surgical resection, thus, avoiding up- or
down-regulation of pRb and p53 proteins due
to DNA damage (9,36). The material comprised
41 adenocarcinomas (AdCs), 41 squamous cell
carcinomas (SqCs) and 5 undifferentiated large
cell carcinomas (ULs). Tumors were classified
according to the World Health Organization cri-
teria and TNM system (37). Clinicopathological
features of the patients are presented in Table 1.
Immunohistochemistry (IHC)
ANTIBODIES. For immunohistochemical analy-
sis the following antibodies were used:
 LM95.1.
∆ Class: Immunoglobulin G (IgG) 
∆ mouse monoclonal
∆ epitope: pRb 
∆ Calbiochem, Biodynamics, Greece
 DO7 
∆ Class: IgG2b 
∆ mouse monoclonal 
∆ epitope: residues 1–45 of p53 
∆ Dako, Kalifronas, Greece
 SMP14 
∆ Class: IgG1 
∆ mouse monoclonal 
∆ epitope: residues 154–167 of MDM2
∆ Santa Cruz, Bioanalytica, Greece)
 MIB-1 
∆ Class: IgG1 
∆ mouse monoclonal 
∆ epitope: Ki-67 nuclear antigen 
∆ Oncogene Science, Biodynamics, Greece.
METHOD. Immunohistochemistry was per-
formed according to the indirect streptavidin-
biotin-hyperoxidase method, as previously de-
scribed (24). 
CONTROLS. Lung carcinoma specimens from
our previous study (24), with well character-
ized pRb, p53 and MDM2 status, were used as
controls for corresponding protein reactivity.
Furthermore, in each set of immunoreactions
the corresponding IgG fraction of unrelated
specificity was used as negative control for the
method. 
EVALUATION. For scoring pRb, p53, MDM2
and Ki67 expression, we used previously pub-
lished criteria (38,24).
(a) pRb: Cytoplasmic reactivity was disre-
garded and only nuclear staining
above any cytoplasmic background
was considered as evidence of protein
expression. The samples were divided
into two categories: normal (No), in
which more than 90% of the tumor
nuclei were stained, and abnormal
(Ab), when there was absence of nu-
clear staining in a portion of (hetero-
geneous) or in the entire (homoge-
neous) tumor section. In addition,
admixed non-neoplastic cells showed
nuclear reactivity. A mosaic pattern of
staining with absence of immunoreac-
tivity in a proportion of tumor cells
was not interpreted as abnormal (38).
(b) p53 and MDM2: Tumors were con-
sidered p53 positive [p53(P)] when
more than 20% of the tumor cells
showed nuclear staining, whereas, car-
cinomas were considered MDM2 posi-
tive [MDM2(P)] when the percentage
of stained cancerous cells was signifi-
cantly higher than that of the adjacent
normal tissue (24). The latter criterion
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Table 1. Summary of pRb, p53, MDM2 status, kinetic parameters, ploidy status and patients’
clinicopathological features
Sample Sex Age Smoking pRb Status p53 Status
AIm SSCP Defective Gene
IHC D13S153 IHC Analysis Exon Mutation
19 M 70 YES No LOH N 
20 M 66 YES No LOH N  9 not examined
22 M 70 YES No N 
31 M 64 YES No LOH N 
36 M 57 NO No N 
45 M 57 YES No ho N 
46 M 68 NO No H N 
51 M 48 YES No H N 
54 M 65 YES No LOH N 
62 M 57 YES No ho N  8 codon 270, TTT - ATT
66 M 58 YES No LOH N 
80 M 75 YES No N
81 M 68 YES No N
13 M 61 YES No N 
21 M 70 YES No H N 
30 M 75 YES No N 
32 M 42 YES No N  5 codon 163, TAC - TGC
37 M 71 NO No LOH N 
39 M 56 YES No H N 
40 M 54 YES No N 
41 M 67 YES No N  4 codon 110, CGT - CT
43 M 60 NO No N  4 codon 60, CCA - CCT
44 M 72 NO No H N  6 codon 213, CGA - _GA
50 M 62 NO No ho N 
79 M 72 YES No N
82 M 74 YES No N
83 M 59 YES No N
84 M 47 YES No N
18 F 69 NO No P  7 codon 248, CGG - TGG
13 M 64 YES No H P  7 codon 248 CGG - CTG
24 M 62 YES No ho P  4 codon 74, GCC - ACC
38 M 53 YES No P 
52 M 72 YES No LOH P  8 codon 273, CGT - CAT
67 M 71 NO No H P 
71 M 67 YES No P
72 M 73 YES No P
73 M 67 YES No P
74 M 74 YES No P
15 M 61 YES No P  7 codon 244, GGC - TGC
17 M 64 YES No LOH P  8 codon 273, CGT - CTT
10 F 68 YES No LOH P  4 codon. 93,  CTG - ATG
11 M 70 YES No LOH P  8 codon 280, AGA - ATA
16 M 63 YES No H P 
17 M 64 YES No H P 
18 M 73 YES No H P  7 codon 230, ACC - AAC
26 M 63 YES No P  6 codon 196, CGA - CCA
42 M 76 YES No LOH P  5 codon 157, GTC - TTC
59 M 65 YES No LOH P  5 codon 143, GTG - GCC
61 M 59 YES No LOH P 
68 M 61 YES No P 
69 F 50 YES No P
70 M 66 YES No P  7 codon 233, CAC - TAC
23 M 79 YES Ab LOH N 
25 M 63 NO Ab H N 
Table 1. Summary of pRb, p53, MDM2 status, kinetic parameters, ploidy status and patients’
clinicopathological features
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(Continued)
p53 Status MDM2 Status PI AI Ploidy Clinicopathological Features
Amino Patients
Acid AIm mRNA “Follow
Substitution D17S179E IHC Level % % Histology LN Stage Up”*
ho N NE NI 10,6 D AD NO I 134
NI N NE 24,6 13,5 D SQ NO I 134
N NE 46,6 1,5 D AD NO I 134
ho N OE 21,2 13 D AD NO I 110
N NE 28,8 A AD YES III 110
ho N NE 32,9 8,9 D AD YES II 127
ho N NE NI D AD NO I 129
H N NE 20,0 2,9 D AD YES II 115
LOH N NE 32,2 3,1 NI SQ NO I 128
F - F LOH N NE 41,4 1,4 A SQ NO I 113
LOH N NE 33,3 2,3 A SQ YES II 113
N NE 29,2 1,2 D SQ NO I 164
N NE 19,0 1,1 D AD NO I 148
P OE 28,3 1,6 A SQ NO I 137
LOH P OE 34,5 NI D SQ YES III 111
P OE 28,8 5,2 D UL NO I 132
Y - C P OE 26,4 0,7 A AD YES III 130
NI P OE 28,9 3,2 A AD YES II 112
ho P OE 54,0 0,9 D SQ YES III 119
P NE 31,0 A UL NO I 118
FS P OE 38,0 0,5 A SQ NO I 130
P - P P OE 21,4 3,5 A AD YES II 130
FS ho P OE 22,3 0,7 A AD YES III 114
H P NE 18,1 1,4 D AD YES II 127
P 33,7 A SQ YES II 114
P 28,7 A SQ YES II 140
P 13,7 2,6 D AD YES III 169
P 40,9 0,6 D SQ NO I 167
R - W N NE 31,0 1,4 D AD NO I 134
R - L ho N NE 32,8 D SQ YES III 118
A - T LOH N NE 26,7 0,8 NI SQ NO I N/A
N NE 39,3 3 A SQ YES III 130
R - H LOH N NE 39,0 0,6 A SQ NO III 129
ho N NE 20,2 0,6 D AD NO I 124
N 22,1 1,5 NI SQ YES II 140
N NI D AD YES II 117
N 26,2 D SQ — — —
N 20,5 1,5 D AD NO I 169
G -C P OE 32,8 6,3 A AD YES III 112
R - L ho P OE 27,2 1,2 A SQ YES II 135
L - M ho P OE 40,6 1,8 A UL YES II 119
R - I H P OE 36,0 0,7 A SQ NO I 134
NI P OE 4,6 0,8 D AD NO I 117
H P NE 27,3 1,2 NI SQ NO II 134
T - N LOH P OE 43,6 4,8 D SQ YES II 111
R - P P OE 29,2 0,1 A AD YES II 117
V - F NI P OE 43,8 0,6 A SQ YES III 130
V - A LOH P OE 30,4 A AD NO I 125
LOH P OE 24,5 1,1 D AD YES III 126
P OE 59,1 2,1 A SQ YES II 121
P NE NI 0,9 A AD YES II 123
H - Y P NE 36,3 D SQ NO I 163
H N OE 26,7 2,6 D AD YES II 118
ho N NE 21,3 1,4 D AD NO I 133
Table 1. (Continued)
M: Male, F: female; IHC: Immunohistochemistry, No: Normal expression,  Ab: Aberrant expression, P: Positive, N: Negative,
NI: Non Informative; AIm: Allelic Imbalance analysis, LOH: Loss of Heterozygosity, H: Heterozygous, ho: homozygous; SSCP:
Single Strand Conformation Polymorphism analysis, (): indicates possible mutation (no mutation), FS: frameshift; NE:
Normal Expression, OE: OverExpression; PI: Proliferation Index, AI: Apoptotic Index, D: Diploid, A: Aneuploid; SQ: Squa-
mous cell carcinoma, AD: Adenocarcinoma, UL: Undifferentiated Large cell carcinoma, LN: Lymph Node metastasis.
*in months after surgery, () indicates that the patient is alive
Sample Sex Age Smoking pRb Status p53 Status
AIm SSCP Defective Gene
IHC D13S153 IHC Analysis Exon Mutation
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was set because we previously demon-
strated that normal elements of the res-
piratory tract react with MDM2 anti-
bodies (22). The remaining tumors
were scored as negative (N).
(c) Ki-67: Tumor cells were evaluated as
positive when nuclear staining with-
out cytoplasmic background was ob-
served. Proliferation index (PI) was
estimated as the percentage of Ki-67
positive cells in 5 to 7 High Power
Fields (HPF) (counted cells more than
1000). Slide examination was per-
formed by three independent ob-
servers (GR, VG, PF). Intraobserver
variability was minimal (p  0.001).
Microdissection and Nucleic Acids Extraction
MICRODISSECTION. For DNA extraction, con-
tiguous 5 m sections were microdissected as
previously described (24). 
85 M 66 YES Ab N
86 F 68 YES Ab N
27 M 70 NO Ab LOH N  8 codon 282, CGG - _GG
33 M 59 YES Ab N 
34 M 63 YES Ab N 
49 M 53 NO Ab N 
87 M 64 YES Ab N
53 M 60 YES Ab LOH P  9 codon 319, AAG - AAT
78 M 69 YES Ab P
11 M 57 YES Ab H P 
14 M 60 YES Ab H P  7 codon 249, AGG - AGT
16 M 75 YES Ab P  5 codon 151, CCC - CAC
19 M 53 YES Ab LOH P  7 codon 238, TGT - TTT
12 M 70 YES Ab P  7 codon 234, TAC - TGC
14 M 74 YES Ab LOH P  7 codon 239, AAC - ACC
15 M 69 YES Ab LOH P  5 codon 163, TAC - TGC
28 M 60 YES Ab LOH P  5 codon 157, GTC - TTC
29 M 61 YES Ab ho P  4 codon 69, GCT - GGT
35 M 67 YES Ab P 
47 M 71 YES Ab LOH P 
48 M 73 YES Ab P  7 codon 237, ATG - ATA
55 M 52 NO Ab ho P  8 codon 275, TGT - TTT
56 M 58 YES Ab LOH P 
57 M 58 YES Ab H P  5 codon 153, CCC - CAC
58 M 52 NO Ab LOH P 
60 M 64 YES Ab LOH P 
63 F 60 YES Ab P 
64 M 62 YES Ab LOH P 
65 M 56 YES Ab ho P 
75 F 33 YES Ab P
76 M 51 YES Ab P
77 M 69 YES Ab P
12 M 60 YES NI LOH NI 
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DNA EXTRACTION. DNA was extracted from
50 g of neoplastic material using the phenol/
chloroform/isoamylalcohol method (39). 
RNA EXTRACTION. Cancerous material with
more than 90% tumor cells was used for RNA
extraction, because microdissection was not
suitable for RNA handling methods. RNA was
extracted with Trizol reagent (Life Technolo-
gies, AntiSel, Greece) according to the manu-
facturer’s instructions. The quality and quan-
tity of RNA was assessed by formaldehyde
denaturing agarose gel electrophoresis and
spectrophotometry at 260 and 280 nm.
p53 Gene Analysis
In this study, additional mutation analysis 
by single strand conformation polymorphism
(SSCP) and automated sequencing (24) was
performed in samples 62, 32, 44, 24, 70, 27 and
28, which were not examined in our previous
study (24).
Allelic Imbalance (AIm) Analysis of Microsatellite
Loci D13S153 and D17S179E
To examine allelic alterations of RB1 and p53,
we chose two markers: D13S153, which was se-
lected from the Linkage Mapping Set v2.0 (PE-
Table 1. Continued
p53 Status MDM2 Status PI AI Ploidy Clinicopathological Feature
Amino Patients
Acid AIm mRNA “Follow
Substitution D17S179E IHC Level % % Histology LN Stage Up”*
N NI NI SQ YES II 109
N 19,7 0,8 A AD YES II 122
FS LOH P OE 13,3 3,5 NI AD YES I 114
P OE 40,7 0,8 A SQ NO I 114
P OE 34,7 0,5 D AD NO I 132
P OE 36,9 D AD NO I 129
P 23,6 0,5 A AD YES II 110
K- N ho N NE 51,2 2,6 A SQ YES III 115
N 26,0 0,7 D AD NO III 172
H P NE 31,1 4,8 A AD YES III 113
R - S ho P OE NI A UL NO I 110
P - H P 45,6 0,6 A SQ YES II 135
C - F ho P OE 30,3 12 D AD NO I 135
Y - C P OE 29,5 0,9 A SQ NO I 135
N - T ho P OE 38,5 1,3 A SQ YES III 118
Y - C LOH P OE 40,6 1,1 A SQ NO I 134
V - F ho P OE 40,9 1,5 A SQ NO I 133
A- G ho P OE 43,4 2,7 A UL YES III 110
P NE 29,2 0,8 A AD YES I 117
ho P OE 54,4 0,5 A SQ NO I 125
M - I P 44,0 0,5 D SQ NO III 114
C - F ho P OE 43,3 0,8 A AD YES II 110
ho P NE 47,3 0,4 A SQ YES II 111
P - H NI P OE 40,0 1,8 A SQ YES III 118
ho P OE 46,0 0,6 A AD YES II 126
H P OE 38,6 1 A AD YES III 123
P OE 50,6 1 A AD NO III 125
LOH P OE 39,3 1,6 D AD NO I 125
LOH P OE 70,4 0,7 A SQ YES II 122
P 39,1 0,5 A AD YES III 110
P 34,0 0,4 A SQ YES II 111
P 42,1 0,3 D SQ NO II 173
LOH NI NI NI SQ YES III 121
Applied Biosystems, Warrington, U.K.) and
lies within the RB1 gene; and D17S179E, a pen-
tanucleotide marker located within the first in-
tron of p53.
PRIMERS. The D17S179E amplimers (designed
using Oligo-version 4.01, National Biosciences
Inc., Plymouth, MA) produce a 161bp fragment
and their sequences were:
5-AGT AAG CGG AGA TAG TGC CA-3
5-GCA CTG ACA AAA CAT CCC CT-3.
METHOD. The markers were amplified in a
panel of duplex reactions. The reaction mix-
ture consisted of: 1xGeneAmp buffer II,
250M dNTPs, 2mM MgCl2, 0.5M of each
amplimer and 2u AmpliTaq Gold polymerase.
The polymerase chain reaction (PCR) thermal
profile was the following: initial denatura-
tion for 2 min at 95C, 30 cycles of 30 sec at
94C, 30 sec at 55C and 30 sec at 72C, 
followed by a final extension step of 20 min 
at 72C. PCR products were denatured in
loading buffer (size marker ROX-350/dextran
blue/formamide: 1/1/5), at 95C for 5 min 
and analyzed on an ABI-PRISM 377 Auto-
matic Sequencer (PE-Applied Biosystems).
Results were evaluated using the Genescan
and Genotyper software (PE-Applied Biosys-
tems).
EVALUATION. The variability of the reaction
and the establishment of the cutoff level for
scoring allelic imbalance have been previously
described (40). When the allele ratio values
were 	0.65 or 
1.54, samples were scored as
loss of heterozygosity (LOH); whereas, when
their values covered the range 0.77–1.23, 
they were scored as negative. Samples exhibit-
ing values between 1.23–1.54 or 0.65–0.77
were subjected to a second assay and scored as
LOH only when a second positive value was
obtained.
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Table 2. Association among pRb, p53, MDM2, pRb/p53/MDM2 patterns, number of alterations and
clinicopathological features, proliferation index, apoptotic rate and ploidy status
Expression Smoking History Histology Lymph Node Invasion Stage
No Yes p SQ AD UL p   p I II III
pRb IHC Ab 5 28 1.000 14 17 2 0.876 15 18 1.000 13 10 10
No 8 44 25 24 3 24 27 22 17 12
p53 IHC P 4 45 0.064 26 20 3 0.268 21 27 0.660 16 16 16
N 9 27 13 21 2 18 18 19 11 6
MDM2 IHC P 8 49 0.751 26 26 5 0.259 23 34 0.159 21 20 16
N 5 23 13 15 — 16 11 14 7 6
pRb/p53/ No/N/N 2 11 0.295 6 7 — 0.759 9 4 0.615 9 3 1
MDM2
Ab/N/N 1 2 3 — — 1 2 1 2 —
No/P/N 2 8 4 6 — 5 4 4 2 3
No/N/P 4 11 7 6 2 5 10 5 5 5
Ab/P/N — 2 1 1 — 1 1 — — 2
Ab/N/P 2 3 4 1 — 3 2 4 1 —
No/P/P — 14 6 7 1 5 9 4 7 3
Ab/P/P 2 21 9 12 2 10 13 8 7 8
Alterations 0
1
2
3
A, Aneuploid; Ab, Aberrant; AD, Adenocarcinoma; D, Diploid; N, Negative; No, Normal; P, Positive; SQ, Squamous cell carci-
noma; UL, Undifferentiated Large cell carcinoma.
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Multiplex Reverse Transcription (RT)-PCR
To examine the mRNA levels of MDM2 in tumor
and adjacent normal tissues, we performed a
semi-quantitative multiplex RT-PCR method. A
target mRNA fragment was co-amplified with a
larger reference mRNA fragment of a ubiqui-
tously expressed molecule (41). The relative ra-
tios of the amplification products in the tumor
samples reflected the relative proportion of input
mRNAs and were compared with the relative ra-
tios of the corresponding normal tissue (41).
CDNA SYNTHESIS. cDNA from 5g of total
RNA was synthesized using oligo-dT and
MMLV reverse transcriptase (Life Technolo-
gies) according to manufacturer’s instructions. 
PRIMERS. The primers used in the reaction
were the following:
 Target cDNA: The conservative area of the
MDM2 gene, where the nuclear localization
and the nuclear export signals were located,
was amplified (42). The amplimers were: 
∆ 5-AGG TGG GAG TGA TCA AAA GG-3
(Pos. 701); and
∆ 5-CCT GAT CCA ACC AAT CAC CT-3
(Pos. 1026).
 Reference cDNA: A 548 bp -actin fragment
was used as reference. 
METHOD. The PCR reactions were performed in
30l containing 10M Tris-HCl, pH 8.8, 50M
KCl, 1.5 mM MgCl2, 0.1% Triton X-100, 200M
of each dNTP (dATP, dCTP, dGTP and dTTP),
30M of each MDM2 primer, 20M of each 
-actin primer, 5l of the cDNA pool and 1u of
Taq DNA polymerase (Promega, Bioanalytica,
Athens, Greece). The thermal cycle profile was
denaturation at 95C for 2 min before the addi-
tion of Taq polymerase, followed by 25 cycles of
1 min at 95C, 1 min at 60C, and 1 min at 72C.
PCR products were analyzed in 2% agarose gels
stained with ethidium bromide.
Proliferation Index Apoptotic Index Ploidy Status
p Mean (n) StDev p Mean (n) StDev p A D p
0.788 37.88(32) 11.34 0.002 1.174(31) 1.029 0.006 23 9 0.034
30.65(48) 9.95 2.223(41) 2.219 23 25
0.129 36.71(46) 11.32 0.001 1.353(43) 1.289 0.011 31 15 0.037
29.26(34) 9.2 2.390(29) 2.399 15 19
0.426 36.02(53) 11.26 0.001 1.450(48) 1.409 0.004 38 15 0.001
28.68(27) 8.96 2.420(24) 2.459 8 19
0.153 28.59(13) 9.13 0.001 3.460(12) 3.063 0.022 4 10 0.034
22.57(3)8 3.67 1350(3)8 1.236 1 2
28.64(9)8 7.36 1.327(7)8 0.823 2 6
31.25(13) 9.43 1.850(10) 1.584 8 5
38.60(2)8 17.82 1.633(2)8 1.321 1 1
29.84(5)8 11.22 1.329(4)8 1.455 2 2
33.49(13) 12.75 1.824(12) 1.865 9 4
41.74(22) 9.22 1.080(22) 0.972 18 4
28.59(13) 9.13 0.001 3.457(12) 3.063 0.001 3 9 0.011
29.27(25) 8.46 1.629(20) 1.241 12 14
33.11(18) 12.33 1.693(18) 1.665 12 7
41.74(22) 9.22 1.080(20) 0.972 19 4
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CONTROLS. (a) Contamination of RNA solu-
tions with DNA was assessed by perform-
ing PCR reactions directly on RNA. Contam-
inated RNA solutions were treated with
DNAase and/or 4M LiCl2. (b) To avoid possi-
ble RT-PCR intra-assay alterations that could
affect the original transcript ratio (target vs.
reference), two-fold serial dilutions of RNA
solutions were employed in control amplifi-
cations. From these reactions, a low number
of PCR cycles was established in order to 
obtain accurate variations of RNA transcript
ratios.
EVALUATION. The relative ratio of MDM2/
-actin was quantified using an image analy-
sis system (Media Cybernetics, Silver Spring,
MD). Because -actin amplification was not
necessarily similar to that of MDM2, compari-
son of the relative ratios of MDM2 and 
-actin for each sample, between correspond-
ing tumor and normal specimens, was per-
formed [MDM2/-actin (Tumor): MDM2/-actin
(Normal)].
Tdt-mediated dUTP Nick End Labeling 
Assay (TUNEL)
METHOD. Double-strand DNA breaks were de-
tected by TUNEL according to the method of
Gavrieli et al. (43). Briefly, 5m paraffin sec-
tions were mounted on poly-L-lysine coated
slides, dewaxed, rehydrated and incubated for
30 min with 0.3% hydrogen peroxide to
quench the endogenous peroxidase activity.
Pretreatment was carried out by incubating the
sections with Proteinase K (Sigma, Athens,
Greece); (20g/ml) for 15 min at 37C. The la-
beling step was performed with TdT (15u per
slide) (New England Biolabs, Bioline, Greece)
for 1 hr at 37C in 25mM Tris-Cl pH 7.2,
200mM potassium cacodylate, 0.25mM CoCl2,
250mg/ml bovine serum albumin (BSA),
24M biotin-dATP (Life Technologies, Anti-
Sel, Greece). The reaction was stopped by rins-
ing the sections in 20mM EDTA. The next stage
comprised a 30 min incubation in StreptAB
Complex solution (1 : 100 stock biotin solution,
1 : 100 stock streptavidin-hyperoxidase solu-
tion; Dako, Kali-fronas, Greece). For color de-
velopment, we used 3,3-diaminobenzidine
tetrahydrochloride (DAB) as chromogen and
hematoxylin as counterstain.
CONTROLS. For positive controls we used tis-
sue sections incubated with DNAse I prior to
treatment with TdT and, for negative ones, we
used sections incubated in TdT buffer without
the presence of the enzyme.
EVALUATION. Cells were considered to un-
dergo apoptosis when nuclear staining, with-
out cytoplasmic background, was observed.
AI was estimated as the percentage of apop-
totic cells in 10 HPFs (counted cells: 900–
1000). Slide examination was performed by
three independent observers (PF, VG, GR). 
Intraobserver variability was minimal (p 
0.001).
Nuclear DNA Ploidy Analysis
METHOD. The samples were stained according
to the Thionin-Feulgen procedure (44). Briefly,
5m paraffin sections were dewaxed, rehy-
drated in descending alcoholic solutions and
subjected to acidic hydrolysis in 5N HCl at RT
for 1 hr. Then the sections were stained with
Thionin-Schiff’s reagent (0.5% thionin, 0.5%
sodium bisulfide, 0.1N HCl) for 90 min at RT.
Next, specimens were washed three times 
(30 sec, 5 min and 10 min) in freshly prepared
sulfide rinsing solution (0.5% sodium bisul-
fide, 0.05 N HCl) and once under running tap
water for 10 min. An additional rinsing step in
acidic alcohol (70% alcohol, 0.1N HCl) was
used to increase the staining contrast. Finally,
the sections were dehydrated in ascending al-
coholic scale and mounted in a xylene-based
material.
EVALUATION. The measuring procedure was
performed using the Optipath TV-based image
analysis system (Meyer Instruments, Houston,
TX) equipped with a microscope and a video
CCD camera. As internal reference control,
lymphocytes or granulocytes were used. In
each analysis, approximately 100 control and
350 tumor cells were measured. To distinguish
non-diploid cells from diploid, an upper limit
of 2.5c was set for diploid values. Because the
fraction above 2.5c might include proliferating
diploid cells, we also calculated the fraction of
tumor cells with DNA values above the 5c
level, which exceeded those of proliferating
diploid cells. Cases with more than 5% of cells
with DNA content above the 5c limit were con-
sidered aneuploid (45).
Statistical Analysis
The possible associations among pRb, p53 
and MDM2 status, independently, among
pRb/p53/MDM2 patterns and the number of
alterations with PI, logAI, ploidy status and
clinicopathological parameters, were assessed
with the nonparametric Kruskal-Wallis and
Pearson’s Chi-square tests (Tables 2 and 3).
Furthermore, analysis of variance (ANOVA)
was used to evaluate more specifically the pos-
sible association among the number of alter-
ations, and PI and logAI (Table 4). Logistic re-
gression model formulation was applied for
estimating possible associations among the
number of alterations and ploidy status (Table
4). For multiple comparisons among alter-
ations of the protein-network and the kinetic
parameters of the tumors, the Scheffe and the
LSD tests were performed (Table 4); whereas,
multinomial logit models were used to exam-
ine their possible associations with the vari-
ous clinicopathological parameters. Finally,
the Kaplan-Meyer methodology was em-
ployed for assessing the survival curves of the
parameters examined in the present study.
Differences among survival curves were ex-
amined by the log-rank test. All the analysis
was performed with the SAS statistical pack-
age (SAS Institute Inc., Cary, NC). The statisti-
cal difference was considered significant when
the p-value was 0.05. It should be noted that
samples 73 and 85 were excluded from the 
Kaplan-Meyer analysis, since their values were
beyond the limits of the survival test.
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Table 4. Association between PI, AI, PI/AI, ploidy and number of alterations
Analysis of Variance Logistic Regression Analysis
PI logAI Ploidy
Mean Difference(95%CI) p Mean Difference(95%CI) p Odds Ratio(95%CI) p
Intercept 28.61(23.17, 34.09) 0.001 0.973(0.5011.444) 0.001 — 0.121
3 alterations 13.17(6.30, 20.04) 0.001 1.145(1.731, 0.558) 0.001 11.87(2.44, 57.85) 0.002
2 alterations 14.50(2.50, 11.49) 0.204 0.836(1.445, 0.227) 0.008 14.29(0.97, 18.97) 0.055
1 alteration 10.67(6.40, 7.39) 0.842 0.831(1.423, 0.235) 0.007 12.11(0.52, 8.67) 0.298
0 alteration — — —
Multiple Comparisons’ Analysis
PI logAI PI/AI
Mean Difference(95%CI) p Mean Difference(95%CI) p Mean Difference(95%CI) p
Intercept
3 alterations LSD 13.17(6.30, 20.04) 0.001 1.144(1.731, 0.558) 0.001 48.05(15.83, 80.27) 0.004
Scheffe 13.17(3.31, 23.03) 0.004 1.144(1.987, 0.302) 0.003 48.05(1.75, 94.35) 0.039
2 alterations LSD 14.50(2.50, 11.49) 0.204 0.836(1.445, 0.227) 0.008 26.80(6.96, 60.56) 0.118
Scheffe 14.50(5.55, 14.54) 0.652 0.836(1.710, 0.039) 0.067 26.80(21.71, 75.32) 0.147
1 alteration LSD 10.67(6.40, 7.39) 0.842 0.831(1.428, 0.235) 0.007 24.05(8.70, 56.80) 0.147
Scheffe 10.67(8.97, 10.31) 0.998 0.831(1.689, 0.026) 0.061 24.05(23.02, 71.11) 0.546
0 alteration — — *
PI logAI PI/AI
Mean Difference(95%CI) p Mean Difference(95%CI) p Mean Difference(95%CI) p
Intercept
0 alteration LSD 13.17(20.04, 6.30) 0.001 1.144(0.558, 1.731) 0.001 48.05(80.27, 15.83) 0.004
Scheffe 13.17(23.03, 3.31) 0.004 1.144(0.302, 1.987) 0.003 48.05(94.35, 1.75) 0.039
1 alterations LSD 12.49(18.23, 6.75) 0.001 0.313(0.192, 0.818) 0.220 24.00(50.96, 2.95) 0.080
Scheffe 12.49(20.73, 4.25) 0.001 0.313(0.412, 1.039) 0.677 24.00(62.74, 14.73) 0.375
2 alterations LSD 18.67(14.74, 2.61) 0.006 0.309(0.211, 0.828) 0.240 21.25(49.43, 6.92) 0.137
Scheffe 18.67(17.38, 0.04) 0.051 0.309(0.438, 1.055) 0.705 21.25(61.74, 19.24) 0.523
3 alterations — — —
PI: Proliferation Index, AI: Apoptotic Index
*Mean Value: 15.18
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Results
pRb, p53 and MDM2 Analysis
pRb STATUS. Aberrant expression of pRb was
observed in 33 of the 85 informative cases
(39%) (Fig. 2a). Statistical analysis between
pRb staining and clinicopathological parame-
ters did not indicate any significant association
(Table 2). Normal and tumor genomic material
was available from 56 samples for AIm analy-
sis. Twenty-six out of 40 informative cases
(65%) displayed loss of heterozygosity (LOH)
(Fig. 3a). Concordance between pRb protein
loss and AIm was noticed in 12 cases (30%;
Table 1). There was no association between
LOH and clinicopathological data.
p53 STATUS. Expression of p53 was found in 49
out of 85 informative samples (57%). A ten-
dency between p53 immunoreactivity and
smoking history was noticed [45/72 (63%) vs.
2772 (37%); p  0.064, Table 2]. Additional
sequence analysis in our extended database re-
vealed p53 mutations in 31 out of the 70 cases
examined with SSCP analysis (46%; Table 1,
Fig. 4). Twenty-six mutations were missense,
two were silent (cases 43 and 62) and three
were frameshift ones (cases 27, 41 and 44;
Table 1, Fig. 5). Another sample (case 20)
showed tumor-specific mobility shifts in SSCP
analysis, but further sequencing was not per-
formed because material was not available. A
highly significant association was observed be-
A) B)
C)
Fig. 2. Representative immunohistochemical
results (see Methods). (A) Squamous cell lung
carcinoma (case 6) with heterogenous aberrant pRb
expression (see Methods). Streptavidin-biotin per-
oxidase technique with “Rb1” anti-pRb antibody
and hematoxylin counterstain (400). [Thick and
thin] arrows indicate an “Rb1” positive and nega-
tive portion of the tumor area, respectively;
whereas, an “Rb1” positive stromal cell is pointed
by a small arrow. (B) Squamous cell lung carci-
noma (case 3) with MDM2 protein overexpression.
Streptavidin-biotin peroxidase technique with
“SMP14” anti-MDM2 antibody (DAB as chro-
mogen) and hematoxylin counterstain (200). 
(C) Squamous cell lung carcinoma (case 62) with
high proliferative activity (proliferation index, 
PI  41%). Streptavidin-biotin peroxidase tech-
nique (DAB as chromogen) with “MIB-1” anti-
Ki67 antibody and hematoxylin counterstain
(400).
tween p53 gene mutations and p53 immunopos-
itivity (positive vs. negative) [25/40 (63%) vs
7/29 (24%), p  0.004 by Pearson’s Chi-square
test]. DNA from 56 samples was suitable for
AIm analysis at the D17S179E locus. LOH was
observed in 14 out of 21 informative samples
(67%; Fig. 3b). Eight of these cases (57%) were
accompanied by p53 point mutations in the re-
maining allele (Table 1). Because the immuno-
histochemical (IHC) status of p53 was highly
correlated with sequence analysis (p  0.004)
and the number of informative specimens at
the p53 locus was rather low, in the following
associations we considered p53 IHC positivity
as an indicator of p53 gene alterations. 
MDM2 STATUS. Overexpression of MDM2 (P)
was found in 57 out of 85 informative cases
(68%). IHC positivity with SMP14 anti-
body was in concordance with the results ob-
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Fig. 3. Representative results of allelic imbal-
ance analysis (see Methods). (A) With chromo-
some marker D13S153 (case 2). (B) With chromo-
some marker D17S179E (case 21). N: Normal
sample, T: Tumor sample. Loss of heterozygosity
(LOH) is indicated by an arrow.
A)
B)
Fig. 4. Representative results of the single
strand conformation polymorphism (SSCP)
analysis for exons 7(A) and 8(B) of p53 gene on
matched normal-tumor (N-T) samples. The dif-
ferences in the electrophoretic profile of the tumor
samples, compared with the respective normal ones
are marked by arrows.
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tained with the 1B10 MDM2 antibody em-
ployed in our previous study (24). MDM2 im-
munoreactivity was not related to any clinico-
pathological features of the patients (Table 2,
Fig. 2b). The MDM2 mRNA levels were exam-
ined in 68 normal and tumor paired samples
by a semiquantitative multiplex RT-PCR assay
(Table 1). MDM2 mRNA was detected in all
normal and tumor specimens. However, the
analysis revealed in 43 out of 68 informative
cases (63%) significantly higher levels of
MDM2 mRNA in the tumors, compared with
the corresponding normal tissues (Table 1,
Fig. 6). The tumor/normal (T/N) ratio ranged
from 0.8–1.2 for normal MDM2 mRNA level
(normal expression, NE) and 2–6.5 for high
levels of MDM2 mRNA (overexpression, OE). A
highly significant association was found be-
tween MDM2 immunohistochemical positivity
and increased MDM2 mRNA levels [IHC(P)/
mRNA(OE): 41/43 (95%) vs. IHC(P)/mRNA
(NE): 7/25 (28%), p  108 by Pearson’s Chi-
square test].
Analysis of Proliferative Activity
RELATIONSHIP WITH CLINICOPATHOLOGICAL PARA-
METERS. In the present study, proliferative ac-
tivity was reflected by the PI, a well estab-
lished biological marker that quantitatively
estimates the growth of neoplasms. It was as-
sessed with MIB-1, the most reliable antibody
for estimating growth fraction by immunohis-
tochemistry (46,47). The percentages of cells
positive for Ki-67 antigen (80 informative
cases) in the cancerous areas ranged from 4.6%
to 70.4% with a mean value 33.54  11.05
(Fig. 2c). Statistical analysis demonstrated that
PI was significantly higher in SqCs (p  0.001
by Kruskal-Wallis; Table 3; and p  0.001 by
ANOVA; mean difference (MD): 10.233; 95%
confidence interval (CI): 14.786, 5.681) and
smokers (p  0.041 by Kruskal-Wallis, Table 3;
and p  0.044 by ANOVA; MD: 6.95, 95% CI:
0.19, 13.71).
RELATIONSHIP WITH EACH ELEMENT OF THE
pRb/MDM2/p53 NETWORK. The patients with
abnormal expression of each examined mole-
Fig. 6. Representative results of the multiplex
reverse transcription polymerase chain reaction
(RT-PCR) assay (see Methods) employed in or-
der to evaluate the levels of MDM2 mRNA. m:
100bp DNA ladder; 1–2: Matched normal-tumor
case (sample 8) with normal MDM2 mRNA expres-
sion; 3–4 and 5–6: Matched normal-tumor cases
(sample 9 and 10, respectively) with MDM2 mRNA
overexpression.
Fig. 5. Representative automated sequencing
in a squamous cell lung carcinoma (case 70)
with single strand conformation polymorphism
(SSCP) mobility shifts in exon 7. The position of
the p53 mutation is located at codon 233 and
changes CAC (H) to TAC (Y).
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cule (pRb: Ab or p53: P or MDM2: P) dis-
played a significantly higher PI than the cases
with normal status (Table 2, p  0.003; MD:
7.25, 95% CI: 2.46, 12.03 for pRb; p  0.002,
MD: 7.47, 95% CI: 2.75, 12.18 for p53; and 
p  0.004; MD: 7.36, 95% CI: 2.38, 12.32 for
MDM2, by ANOVA).
Apoptotic Index (AI)
RELATIONSHIP WITH PI AND CLINICOPATHOLOGICAL
PARAMETERS. AI ranged from 0.08% to
10.67%, with a mean value 1.771  1.863
(72 informative cases, Fig. 7). No association
between AI and PI was observed by linear re-
gression analysis. Furthermore, apoptosis was
not associated with any of the clinicopatholog-
ical parameters of the patients (Table 3).
RELATIONSHIP WITH EACH ELEMENT OF THE
p53/MDM2/pRb NETWORK. AI was signifi-
cantly reduced when deregulated expression of
each examined molecule was observed (pRb: Ab
or p53: P or MDM2: P Table 2); [p  0.005, MD:
0.588, 95% CI: 0.988, 0.187 for pRB; p 
0.031, MD: 0.459, 95% CI: 0.873, 0.004 
for p53; and p  0.031, MD: 0.476, 95% CI:
0.907, 0.004 for MDM2, by ANOVA].
Ploidy Status
RELATIONSHIP WITH PI, AI AND CLINICOPATHOLOG-
ICAL PARAMETERS. Forty-six of the 80 informa-
tive cases (58%) were evaluated as aneuploid
(Fig. 8). The aneuploid tumors exhibited sig-
nificantly higher PI values and decreased AI
than the diploid ones (p  0.003, MD: 7.41,
95% CI: 2.52, 12.30 for PI; and p  0.030, MD:
0.484, 95% CI: 0.920, 0.005 for logAI by
ANOVA). Aneuploidy was associated with ad-
vanced stages of the disease [stage II and III vs.
stage I: 33/47 (70%) vs. 13/32 (41%), p  0.031
by Pearson’s Chi-square test, Table 3; and p 
0.049, odds ratio: 3.297 (1.293, 12.100) for
stage II; and p  0.021, odds ratio: 3.956
(1.058, 10.276) for stage III in relation to stage
I, by logistic regression analysis] and lymph
node metastases [32/43 (74%) vs. 14/36 (39%),
p  0.003 by Pearson’s Chi-square, Table 3; and
p  0.002, odds ratio: 4.571 (1.754, 11.919) by
logistic regression analysis].
RELATIONSHIP WITH EACH ELEMENT OF THE
p53/MDM2/pRb NETWORK. Aberrant expres-
sion of pRb, p53 and MDM2 overexpression,
independently, were significantly correlated
with aneuploidy (Table 2); [p  0.036, odds ra-
tio: 2.778 (1.068, 7.228) for pRb; p  0.039,
odds ratio: 2.618 (1.047, 6.540) for p53; and 
p  0.0006, odds ratio: 6.017 (2.170, 16.678) for
MDM2, by logistic regression analysis].
Expression Patterns of p53, MDM2 and pRb
EXPRESSION PATTERNS AND CORRELATION WITH CLIN-
ICOPATHOLOGICAL PARAMETERS. We observed 8
out of the 9 theoretically expected patterns
(Table 2). Due to the small number of cases in
each pattern, we arranged the tumors into four
groups according to the alterations detected 
(0, 1, 2, and 3 alterations). The pRb(Ab)/p53(P)/
MDM2(P) immunoprofile was the most fre-
quent one with 23 out of 85 informative cases
(27%; Table 2). It was also the most common
among histological subtypes, carcinomas with
lymph node disease and patients with smoking
history (Table 2). Statistical analysis based on
multinomial-logit model formulation revealed
no significant correlations among the four
groups and the clinicopathological parameters
of the patients. 
RELATIONSHIP WITH PI, AI AND PLOIDY STATUS.
The patients that demonstrated an immuno-
phenotype with three alterations, displayed a
significantly increased PI and reduced AI, com-
pared with those with no defects (Table 4, Figs.
9A, B). Moreover, PI was significantly lower in
Fig. 7. Lung adenocarcinoma (case 5) with
high apoptotic index (6.3%). Tdt-mediated dUTP
Nick End Labeling assay (TUNEL) (3,3-di-
aminobenzidine tetrahydrochloride DAB as chro-
mogen, see Methods) and hematoxylin counterstain
(400).
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the cases with one or two alterations, than those
with three; whereas, AI was statistically de-
creased in the samples with one or two abnor-
malities, than those with none (Table 4, Fig. 9A,
B). Notably, the PI/AI ratio obtained the lowest
value (15.18  9.62, calculated using the values
in Table 1) in the cases with the normal pheno-
type; whereas, the samples with the full abnor-
mal phenotype received the highest PI/AI score
[63.23 (15.8  48.05); Table 4, Fig. 9C]. As far as
ploidy status was concerned, logistic regression
analysis indicated that aneuploidy was associ-
ated only with the aberrant immunoprofile
[pRb(Ab)/ p53(P)/MDM2(P); Table 4].
Survival Analysis
The Kaplan-Meier methodology was used to
estimate the impact of each parameter exam-
ined on the patients survival status. During the
study (follow-up duration up to 67 months) we
observed 38 failures and 45 censored cases. The
median survival was 40 months. Differences
among survival curves were examined using
the log-rank test. The analysis indicated a sig-
nificant association among poor patient out-
come, aneuploidy (p  0.014), stage (p 
0.003) and lymph node invasion (p  0.001;
Table 5).
Fig. 8. Representative diagrams presenting the ploidy status of tumor samples (see Methods). D:
diploid tumor (case 13), A: aneuploid tumor (case 14).
Discussion
The balance between the process of prolifera-
tion and programmed cell death is required for
homeostasis in any cell population. Deregula-
tion of this balance, either by increased prolif-
eration and/or decreased programmed cell
death, can lead to neoplasia (35). The pRb and
p53 proteins play important roles in control-
ling both sides of this equilibrium. Recently, it
was shown that their ability to regulate the
apoptotic procedure is mediated via the MDM2
protein, which interacts directly with both pRb
and p53 (13). The first part of our study exam-
ines the status of these cell cycle regulatory
molecules and their relationship with the ki-
netic parameters of proliferation and apoptosis
in a series of 87 NSCLCs. To the best of our
knowledge, this information in NSCLCs has
not been addressed before.
Abnormal expression of pRb (Ab) and
overexpression of p53 (P) and MDM2 (P)
proteins was detected in 39%, 57% and 68%
of the carcinomas, respectively. The percent-
ages for pRb and p53 are comparable with
those reported (48,49). As for MDM2, by re-
viewing the world literature, we found, be-
sides our previous works (22–24), only two
other immunohistochemical studies in lung
carcinomas (50,25). The results among the
three groups differed considerably, although
Marchetti et al. (50) and Higashiyama et al.
(25) employed the same anti-MDM2 anti-
body. These differences may be due to techni-
cal parameters of the assays and/or criteria of
positivity applied by the authors. In the pre-
sent report, immunohistochemical positivity
of p53 and MDM2 reflected deregulation of
their expression, since a very strong correla-
tion with p53 gene alterations (p  0.004) and
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Fig. 9. Box-plots represent the proliferation index
(PI) (A) apoptotic index (AI) (B) and the PI/AI 
ratio (C) of the tumor groups with 0, 1, 2 and 3 
alterations of the pRb/p53/MDM2 network.
Table 5. Survival analysis
Log-Rank test
Statistic p
pRb 1.665 0.197
p53 10.594 0.441
MDM2 12.981 0.084
Proliferation Index 0.697 0.321
Apoptotic Index 2.440 0.833
Ploidy Status 16.045 0.014
Smoking History 10.232 0.630
Histology 14.585 0.101
Lymph Node invasion 23.547 0.001
Stage 11.406 0.003
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increased MDM2 mRNA levels (p  108), re-
spectively, was observed.
The data from the LOH study at the p53 lo-
cus were not taken into consideration in our
analysis, due to the high percentage of ho-
mozygous (non-informative) samples. How-
ever, it should be mentioned that 57% of the
cases with LOH were accompanied with point
mutations in the remaining p53 allele, a find-
ing that is in keeping with the “two-hit” hy-
pothesis of oncosuppressor gene inactivation
proposed by Knudson (51). The levels of 
MDM2 mRNA were examined with a sensitive
multiplex RT-PCR assay using as the target se-
quence a conservative area of MDM2 (see “Ma-
terial and Methods” section). This area lies 
near the center of the molecule (131-238aa) 
and includes the nuclear localization and ex-
port signals that are necessary for nucleo-cyto-
plasmic shuttling of MDM2 (42). By examin-
ing this region, we excluded the possibility of
false-negative results due to alternative splice
variants of MDM2 with truncated the –NH2 or
–COOH terminal portion of the protein (16).
As MDM2 immunohistochemical analysis was
performed with an antibody directed against
the above region of the molecule (154–167aa)
and high concordance with increased MDM2
mRNA levels was observed, we assume that at
least one of the known MDM2 isoforms,
shown to exist in lung carcinomas, is overex-
pressed in this series (23). It is noteworthy 
that in nine cases a discordance between
MDM2 protein expression and MDM2 mRNA
analysis was found (Table 1). This incompati-
bility in the seven tumors with MDM2 stain-
ing and normal mRNA levels may be due to
enhanced MDM2 mRNA translation (52);
whereas, in the two cases with high MDM2
mRNA levels and lack of protein expression 
it may be attributed either to technical draw-
backs or post-translational events, such as 
targeted-degradation by p14ARF (53,54). At 
this point, it should be mentioned that we and
others have shown that MDM2 gene amplifi-
cation is a very rare phenomenon in lung 
carcinomas (22,23,25,49). As far as pRb is 
concerned, immunohistochemistry has been
proposed to be the most sensitive method for
evaluating RB1 gene inactivation (55), because
it examines the protein at a single-cell level.
and the large size of the gene (27 exons fused
in a 4.7Kb transcript) makes sequence analysis
a difficult procedure. However, in a portion of
our samples, we performed an allelic imbalance
analysis of RB1 using the internal chromosomal
marker D13S153 and correlated the findings
with the immunohistochemical profile of pRb.
Correlation between allele loss and aberrant
pRb expression was noticed only in 30% of the
cases examined. This puzzling inconsistency
has also been observed by others in lung
(55,56), breast (57) and bladder (58) carcino-
mas, thus, raising some doubt as to the signifi-
cance of LOH in such tumors. One possible ex-
planation for this finding is that minor deletion
within the aforementioned locus, which lies
within the large intron downstream of exon 2,
would result in LOH, but leave the coding re-
gions intact. In addition, unmasking of a reces-
sive mutation by allele loss cannot be excluded,
thus, providing another mechanism behind RB1
inactivation in NSCLCs. If the later hypothesis
is proven, then the frequency of RB1 inactiva-
tion is higher than that estimated by IHC.
The comprehensive analysis of the three
cell cycle regulatory molecules revealed 8 of
the 9 theoretically expected patterns (Table 2).
Concurrent alterations in all three proteins was
the most frequent pattern and represented ap-
proximately 27% of the cases, followed by 
the pRb(No)/p53(N)/MDM2(P) and pRb(No)/
p53(P)/MDM2(P) profiles, which comprised
18% and 17% of the patients, respectively. The
fourth most common pattern, with 15% of the
tumors, did not demonstrate any immunohis-
tochemical alterations in the proteins exam-
ined, although, in three circumstances, LOH at
the p53 locus was noticed (cases 54, 62 and 66).
This latter finding should be kept under con-
sideration since Venkatachalam et al. recently
reported that reduction in p53 levels may be
sufficient to promote tumorigenesis (59). In the
present extended series of NSCLCs, the rela-
tionship among the patients’ clinicopathologi-
cal parameters and the various immunoprofiles
did not demonstrate any significant correlation
confirming our previous findings (24). How-
ever, the high frequency of multiple alterations
(two and three molecules affected, 44%), along
with the absence of correlation with clinical
stage (Table 2), suggest that deregulation of the
pRb/p53/MDM2 pathway may be a relatively
early event in the development and progres-
sion of some NSCLCs. 
Examining the kinetic parameters of the
tumors in association with the various im-
munophenotypes, we observed that the (PI/
AI) ratio obtained its highest mean value
(PI/AI 63.23) in the group of carcinomas
with simultaneous alterations in all three ele-
ments of the network; whereas, in the tumors
with the normal phenotype it received the
lowest one (PI/AR  15.18; p  0.004; Table
4; Fig. 9C). Moreover, the former pattern
[pRb(Ab)/ p53(P)/MDM2(P)] acquired the
highest PI (p  0.001) and the lowest AI 
(p  0.001) scores (Tables 2 and 4; Figs. 9A,
B). Together, these findings suggest that coin-
cidental deregulated expression of all mem-
bers of the pRb/p53/ MDM2 network confers
an additive effect on tumor growth. Therefore,
on the one end of this scheme, the cancerous
cell retains the trimeric pathway intact, thus,
pRb controls the activities of the E2F/DP tran-
scription factor family (6) and protects wt p53
from MDM2-targeted degradation (13). Con-
sequently, depending on the cellular context,
such as excess activity of cellular oncoproteins
(2), wt p53 is capable of promoting either cell
cycle arrest or inducing apoptosis, hence,
maintaining a relatively low PI/AI ratio. On
the other end of this hypothetical scenario, the
tumor will have a complete growth advan-
tage. Because p53 protein is mutated, the
MDM2 protein is overexpressed and free from
the surveillance of pRb and, thus, is able to
exert its tumorigenic effects (13–15) and pRb
suppression on the E2F/DP family will be re-
lieved (6). Furthermore, there is increasing
evidence that mutations not only eliminate the
suppressor activity of the wt p53 protein, but,
may also gain function and convert it into an
oncogene (60–63). The mechanisms proposed
to underlie this positive dominant effect of mu-
tant (mt) p53 include anomalous transcrip-
tional activity (64) or, as we will discuss later,
enhancement of genomic instability (65,32).
Relative to the first, mt p53 proteins have been
shown in transient transfection assays, to trans-
activate the proliferating cell nuclear anti-
gen (PCNA) gene, which encodes a 36kDa nu-
clear polypeptide that is an auxiliary protein 
for DNA polymerase  (64). This functional as-
sociation between mt p53 and a cell proliferat-
ing gene, like PCNA, may possibly represent
one of the processes that reside behind the pos-
itive correlation between p53 staining and in-
creased PI observed in this (p  0.001, Table 2)
and other studies in NSCLCs (66–68). Never-
theless, there are reports that do not show such
an association (69–71). 
Another interesting finding was that the
groups of carcinomas with impaired expres-
sion of one or two molecules attained PI/AI 
ratios values clustered in a narrow range from
39.22 (15.18  24.05, Table 4) to 41.98 (15.18 
26.80, Table 4), which is placed in the middle
of the scores exhibited by the normal and full
abnormal phenotypes. (Table 4, Fig. 9C). Fur-
ther analysis demonstrated that these tumors
had significantly lower AI, but similar PI val-
ues, compared with those noticed in the nor-
mal pattern (Table 2). This latter observation
insinuates that the apoptotic pathway is more
susceptible to defects of the network than the
cell proliferation machinery. This assumption
is in agreement with the recent findings of
Hsieh et al., who demonstrated that one of the
main activities of the pRb/MDM2/p53 path-
way was the protection of the p53 apoptotic
function (13). On the contrary, cell prolifera-
tion is significantly deranged only when all
members of the network are deregulated, sug-
gesting a counterbalance mechanism. This is a
rational conclusion when one of the two onco-
suppressors is functional, but what happens
when both of them are impaired and MDM2 is
intact? Although, in the present work, only
two cases fell in this category, they obtained
the second highest PI scores (Table 2). This is
in accordance with the results of Kinoshita et
al., who showed that high proliferative activ-
ity in p53-positive NSCLCs was further in-
creased when associated with loss of pRb or
p16 expression (67). Therefore, since the re-
maining pRb(Ab)/p53(P) cases were included
in the full abnormal immunophenotype group,
we can presume that deregulated expressions
of pRb and p53 act in a synergistic manner on
proliferative activity, which is further en-
hanced by MDM2 overexpression. 
The model suggested above might ex-
plain aggressive clinical behavior observed in
various carcinomas, including NSCLCs with
coincident altered status of pRb and p53
(72–74) and faster tumor development in
RB1, p53 transgenic mice than in mice
deficient only in RB1 or p53 (75), but it also
raises several questions. First, what is the
role depicted by the transcription factors of
the E2F/DP family and, particularly, E2F1 on
cell proliferation and apoptosis in the cases
with aberrant pRb expression? There is sub-
stantial evidence that E2F1 may act as an
oncogene and a potent inducer of apoptosis in
vivo (reviewed in 76). Second, how is MDM2
expression triggered in the tumors where its
upstream effector, p53, is mutated and why is
228 Molecular Medicine, Volume 6, Number 3, March 2000
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mutant p53 not degraded by MDM2 in these
samples (10,11)? Third, in view of Brown’s
and associates’ recent finding that MDM2 can
induce cell cycle arrest (27), which conditions
promote its growth-inhibitory functions and
which its growth-stimulating ones? 
Relative to the first question, it has been
shown in transgenic mouse models that, when
the pRb family is disrupted, E2F1 expression
is deregulated, inducing increased prolifera-
tion and p53-mediated apoptosis (76,77), the
later probably via p14ARF (78). In these animal
models, loss of E2F-1 dramatically lessens
apoptosis, but does not lead to tumor onset,
due to a parallel decrease in proliferation. This
suggests that a delicate E2F-1-dictated balance
between proliferation and apoptosis occurs
(77). Moreover, several studies convincingly
demonstrate that the tumor suppressor or
oncogenic function of E2F1 is determined in a
tissue-specific manner (76). Thus, perhaps un-
der certain conditions, such as the overexpres-
sion of the appropriate growth factor/receptor
system accompanied by loss of the p53 apop-
totic function and overexpression of MDM2
(79), the E2F downstream signals weight in
favor of proliferation rather than apoptosis.
Similar situations occur in the cases of c-myc
(80,81) and c-mos proto-oncogenes (82). Exper-
iments are underway in our laboratory to de-
termine the status of E2F1 in our series of
NSCLCs. As for the second question, we and
others have shown that certain mutant p53
proteins have the ability to transactivate di-
rectly (83,84) or indirectly (85) the MDM2
gene. In addition, Shaulian et al. (86), recently
reported a p53-independent mechanism of
MDM2 induction by the basic fibroblast
growth factor (bFGF). Perhaps such a mecha-
nism could account for MDM2 overexpression
in the cases with mutant nonfunctional p53
protein, since expression of bFGF and its re-
ceptor has been observed in a significant pro-
portion of NSCLCs (87). Further studies are
needed to examine whether similar actions are
exerted by other growth factors as well. IHC
codetection of MDM2 with mt p53 does not
necessarily imply complex formation and
eventual degradation. The amount of p53
bound with MDM2 is controlled by various
modifications, including phosphorylations,
dephosphorylations and acetylations, which
may be impaired in the context of a cancerous
cell (88), or even the existence of other
MDM2-variants that do not possess p53-bind-
ing domain (16). Moreover, an additional
mechanism, which could prevent the associa-
tion of the two proteins, is deregulated expres-
sion of the molecules necessary for p53-
MDM2 interaction; such is the case of the
p300/CBP protein (89). The recent identifica-
tion of tumor suppressor-like mutations in the
p300 gene in colorectal and gastric carcinomas
provides support for such ideas (90). Finally,
Brown and associates (27) showed that MDM2
blocks G0/G1-S transition in nontumor cells;
whereas, tumor-derived cells are relatively in-
sensitive to the growth inhibitory effects of
MDM2. This discrepancy may be due to ge-
netic defects, which render cancer cells toler-
ant to MDM2. On the other hand, MDM2 pro-
tein(s) in tumors may harbor inactive growth
inhibitory domains (ID) as a result of splice
variants (16) or mutations. Schlott et al. (91)
detected mutations of MDM2 in several cancer
samples near ID2.
In the second part of this study, we inves-
tigated the relationship between the cellular
DNA content (ploidy) of the carcinomas and
the expression patterns of the pathway. The
full abnormal phenotype was associated sig-
nificantly with aneuploidy (p  0.011 by
Kruskal-Wallis, Table 2 and p  0.002 by lo-
gistic regression analysis, Table 4). A ten-
dency was observed when the expression of
two components was altered (p  0.055 by lo-
gistic regression analysis, Table 4). Interest-
ingly, these findings are in parallel with those
concerning the proliferative activity and the
apoptotic rate analysis, mentioned above, and
support the concept that p53, MDM2 and pRb
form a tightly regulated network (13). Fur-
thermore, by comparing the individual associ-
ations of each element with the DNA content
status and that of the pRb(Ab)/p53(P)/
MDM2(P) pattern (Tables 2 and 4), we no-
ticed that the latter association with aneu-
ploidy was stronger than that of abnormal p53
(p  0.037 by logistic regression analysis,
Table 2) and pRb staining alone (p  0.034 by
logistic regression analysis, Table 2), but not
from overexpressed MDM2 (p  0.001 by lo-
gistic regression analysis, Table 2). By further
analyzing the relationship of each of the above
factors with the ploidy status of the carcino-
mas, several comments can be made. It is well
established that wt p53 is a major checkpoint
protein involved in DNA, spindle and centro-
some surveillance (92). The failure of such a
checkpoint may lead to genomic instability.
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9
7
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However, when reviewing the literature, we
found that the studies that deal with the asso-
ciation between p53 status and DNA content
levels in NSCLCs reach controversial conclu-
sions (45,68,69,93–96). Notably, in these re-
ports, p53 was examined only by immunohis-
tochemistry; thus, the exact nature of p53
overexpression was not clear. Recently, Gual-
berto et al. (32), suggested that the type of p53
mutations may play an important role in
defining the ploidy status of a cell by main-
taining or disrupting the spindle checkpoint
control. Particularly, they showed that certain
conformational mutations [class II mutants ac-
cording to Cho et al. (97)], in fibroblasts from
Li-Fraumeni syndrome patients, exhibited a
dominant gain of function activity that gener-
ated chromosomal instability; whereas muta-
tions in the specific DNA binding domain
[class I mutants (97)] and truncations dis-
played a normal spindle checkpoint response
in which cells accumulated with diploid con-
tent of DNA (32). In the present study, the ma-
jority of p53 mutations, regardless of class,
were associated with aneuploidy, although in
two cases, mutations at codon 248 (class I mu-
tations) were correlated with diploidy, a find-
ing also demonstrated by Gualberto et al. (32;
Table 6). Furthermore, four class II mutations,
at codons 238 (case 9), 230 (case 18), 237 (case
48) and 233 (case 70), were accompanied with
normal DNA content (Table 6). In a late re-
port, Agapova et al. (30) demonstrated that
class I mutant Trp248 caused an increase in
the frequency of chromosomal breaks and
emergence of polyploidy in the human hered-
itary non-polyposis colon cancer (HNPCC)
cell line LIM1215. The findings suggest that,
apart from the nature of the p53 mutations,
other additional factors may also determine
the ability of the cell to monitor correct spin-
dle assemblage. Alterations in other mitotic
checkpoint genes, such as mutations in the
human homologue of the yeast BUB1 gene,
support the later view (99). In addition, the
recent identification of 14-3-3  protein, a p53
downstream target which is involved in G2/M
phase progression, points to the investigation
of defects in p53-dependent G2/M effectors in
human tumors (100). Besides p53, current
data indicate that pRb plays an essential role
in inducing G1/S cell cycle arrest after DNA
damage. This effect is independent from
p21WAF1/cip1 activation (36), hinting that si-
multaneous deregulated expression of p53
and pRb may lead to premature entry into the
S phase. Inappropriate entry into the replica-
tion phase results in chromosomal instability,
since DNA damage due to extrinsic or intrin-
sic causes can be efficiently repaired only dur-
ing the G1 phase. Moreover, shortening of G1
phase may actually cause DNA damage due to
failure of the cell to activate enough repli-
cation forks, commencement of replication 
with low levels of nucleotides, or reduced 
activity of ribonucleotide reductase (RNR)
(1,29). Consequently, the importance of p53
and pRb for maintaining the integrity of the
genome, along with the fact that MDM2
seems to play a pivotal role by interacting
with both molecules, suggest that overexpres-
sion of pRb could lead to chromosomal insta-
bility by over-riding their checkpoint func-
tions. 
Finally, the relationship among the kinetic
parameters, the ploidy status of the tumors, the
clinicopathological parameters, and outcomes
of the patients revealed that proliferative activ-
ity was significantly associated with histology
(higher PI in SqCs than AdCs) and smoking
habits. Aneuploidy was also correlated with
clinical stage and poor overall survival. A num-
ber of studies have examined the utility of
measuring the tumor proliferation index as a
prognostic marker in patients with NSCLCs
with controversial results (99–102). The associ-
ation found between PI and SqCs has also
been reported by two other groups (46,102)
and may ascribe the different biological pro-
files, which characterize SqCs and AdCs of the
lung (48). The correlation observed with smok-
ing possibly reflects the association found be-
tween smoking and p53, well known target of
tobacco derivatives (3). The adverse effect of
aneuploidy on patients outcome has been
demonstrated by the majority of groups that in-
vestigated this topic (103–109) and probably
illustrates the cooperative impact of deregu-
lated tumor kinetics, found in the current (see
“Results”) and other studies (110), and im-
paired immune surveillance remarked by cer-
tain researchers (111).
In conclusion, this study provides evi-
dence that, in a subset of NSCLCs, simulta-
neous deregulation of the pRb, p53 and 
MDM2 proteins confers an additive effect on
tumor growth and chromosomal instability 
(Fig. 10). Whether or not this process is applic-
able in other malignancies, remains to be
proven.
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